EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic potential of stem cell‐derived somatic cells to treat metabolic dysfunction‐associated steatotic liver disease and diabetes

Eduardo H Gilglioni iD, Mayank Bansal, Wadsen St-Pierre-Wijckmans iD, Stephanie Talamantes, Alvile Kasarinaite, David C Hay, Esteban N Gurzov iD

Obesity Reviews · 2025

DOI: 10.1111/obr.13899 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Obesity Reviews, 2025. Verfasst von Eduardo H Gilglioni und 6 weiteren Autor:innen. Beteiligte Einrichtung: Signal Transduction and Metabolism Laboratory, Université libre de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: Fatty Liver, Hepatocytes, Insulin-Secreting Cells, Diabetes Mellitus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 160 Literaturangaben. Gefördert von: Fonds De La Recherche Scientifique, ULB Foundation, Horizon Europe - European Research Council (ERC) Consolidator grant METAPTPs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developments in basic stem cell biology have paved the way for technology translation in human medicine. An exciting prospective use of stem cells is the ex vivo generation of hepatic and pancreatic endocrine cells for biomedical applications. This includes creating novel models ‘in a dish’ and developing therapeutic strategies for complex diseases, such as metabolic dysfunction‐associated steatotic liver disease (MASLD) and diabetes. In this review, we explore recent advances in the generation of stem cell‐derived hepatocyte‐like cells and insulin‐producing β‐like cells. We cover the different differentiation strategies, new discoveries, and the caveats that still exist regarding their routine use. Finally, we discuss the challenges and limitations of stem cell‐derived therapies as a clinical strategy to manage metabolic diseases in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverHepatocytesInsulin-Secreting CellsDiabetes MellitusStem Cell TransplantationDiabetes Mellitus, Type 2Stem CellsHumansCell DifferentiationAnimals

Stichwörter der Autor:innen

MASLDdiabetesmetabolic cellsstem cells

Autor:innen und Institutionen

  • Signal Transduction and Metabolism Laboratory, Université libre de Bruxelles, Brussels, Belgium.
  • Institute for Regeneration and Repair, Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.
  • WELBIO Department, WEL Research Institute, Wavre, Belgium.

ORCID-Profile: Eduardo H Gilglioni, Wadsen St-Pierre-Wijckmans, Esteban N Gurzov

Förderung

  • Fonds De La Recherche Scientifique
  • ULB Foundation
  • Horizon Europe - European Research Council (ERC) Consolidator grant METAPTPs
  • Juvenile Diabetes Research Foundation (JDRF) Career Development Award
  • Juvenile Diabetes Research Foundation United States of America

Zitieren

APA

Gilglioni, E. H., Bansal, M., St-Pierre-Wijckmans, W., Talamantes, S., Kasarinaite, A., Hay, D. C., & Gurzov, E. N. (2025). Therapeutic potential of stem cell‐derived somatic cells to treat metabolic dysfunction‐associated steatotic liver disease and diabetes. Obesity Reviews. https://doi.org/10.1111/obr.13899

Vancouver

Gilglioni EH, Bansal M, St-Pierre-Wijckmans W, Talamantes S, Kasarinaite A, Hay DC, et al. Therapeutic potential of stem cell‐derived somatic cells to treat metabolic dysfunction‐associated steatotic liver disease and diabetes. Obesity Reviews. 2025. doi:10.1111/obr.13899

BibTeX
@article{Gilglioni2025,
  author = {Gilglioni, Eduardo H and Bansal, Mayank and St-Pierre-Wijckmans, Wadsen and Talamantes, Stephanie and Kasarinaite, Alvile and Hay, David C and Gurzov, Esteban N},
  title = {Therapeutic potential of stem cell‐derived somatic cells to treat metabolic dysfunction‐associated steatotic liver disease and diabetes},
  journal = {Obesity Reviews},
  year = {2025},
  doi = {10.1111/obr.13899}
}
Kostenlos starten →